Macrophage polarisation: the impact of M1 versus M2 polarisation on host innate immune responses to bacterial infection by Foley, Niamh M.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Macrophage polarisation: the impact of M1 versus M2 polarisation on
host innate immune responses to bacterial infection
Author(s) Foley, Niamh M.
Publication date 2015-12
Original citation Foley, N. M. 2015. Macrophage polarisation: the impact of M1 versus
M2 polarisation on host innate immune responses to bacterial infection.
MD Thesis, University College Cork.
Type of publication Doctoral thesis






Macrophage Polarisation: the impact of M1 versus M2 polarisation on host innate 
immune responses to bacterial infection 
 
 
A thesis submitted to the National University of Ireland for the MD degree 
examination of: 
 






Prof HP Redmond 
Dr JH Wang 
 
AFFLIATION: 








I would like to take this opportunity to thank everyone who helped and supported me in 
writing this research MD. I would like to express my extreme gratitude to Professor 
Redmond, who guided me through this. His mentorship, patience and encouragement were 
invaluable, not only during my time in research but also in my fledgling surgical career. I am 
particularly grateful to Dr Wang for his valuable and constructive suggestions during the 
planning and execution of this research and especially for always being on hand to answer 
my innumerable questions. My special thanks are extended to Qiondi Wu and Siobhan 
Blankson for their laboratory assistance. 
  
 I would like to thank my colleagues in the research laboratory who, over time became 
friends, especially Gaitri Sadadcharam who guided me through my first few months and 
Caitriona Lyons, who was always available to answer any number of enquiries. A special 
acknowledgement and thanks is reserved for Grace O’Callaghan, without whose 
encouragement and support, I would not have completed this thesis. Ultimately, I would like 








Table of Contents 
 
Declaration         i 
Acknowledgements        ii 
Abstract         vii 
Abbreviations        ix 
List of Publications        xiv 
 
Chapter 1: Introduction 
1.1 Sepsis         1  
1.1.1 Definition        1  
1.1.2 Incidence and mortality of sepsis    4  
1.1.3 Risk factors in sepsis      5 
1.1.4 Aetiology of sepsis      6 
1.1.5 Bacterial sepsis      6 
1.1.6 Classification of bacteria     6 
1.1.7 Aetiology of bacterial sepsis     7 
1.1.8 Pathophysiology of sepsis     8  
1.1.9 Treatment of sepsis      8 
1.1.10 Antibiotic therapy      9 
1.1.11 Early goal directed therapy     9 
1.1.12 Immune modulation      9 
iv 
 
1.2 Immune response to sepsis      10  
1.2.1 Adaptive immune response     11 
1.2.2 Innate immune response to sepsis    11 
 
1.3 Macrophages        13 
1.3.1 M1 macrophages (classically activated)   15 
1.3.2 Signaling in M1 macrophages    15 
1.3.3 M2 macrophages      19 
1.3.4 Role of macrophages in the immune system   21 
1.3.5 Macrophage polarisation and its role in sepsis  22 
 
1.4 Signaling pathways involved in sepsis    24 
1.4.1 Toll-like receptors      24 
1.4.2 TLR4        24 
1.4.3 TLR2        25 
1.4.4 TLR signalling in sepsis     25 
1.4.5 MyD88 dependent pathway     26 
1.4.6 P38 MAPK signalling in sepsis    27 
 
1.5 Endotoxin Tolerance       30 
1.5.1 The role of endotoxin tolerance in sepsis   30 
1.5.2 Similarities between endotoxin tolerance and the  
M2 macrophage polarisation pathway   31 




Chapter 2: Materials and Methods      46 
2.1  Reagents        46 
2.2 Bacteria        47 
2.3 Isolation of murine bone marrow-derived macrophages  47 
2.4 Polarisation of M1 and M2 phenotypes    48 
2.5 Stimulation of polarised M1 and M2 macrophages   48 
2.6 Enzyme-linked immunosorbant assay    48 
2.7 Western blot analysis       49 
 2.7.1 Sample preparation      49 
 2.7.2 Bicinchoninic acid (BCA) assay    49 
2.7.3 Sodium Dodecyl Sulfate Polyacrylamide Gel  
Electrophoresis (SDS-PAGE) and Western blotting   50 
2.8 Statistical analysis       51 
  
Chapter 3: Results        52 
3.1 Cytokine Results       52 
 3.1.1 IL-6 secretion in naïve and polarised macrophages  53 
 3.1.2 IL-10 secretion in naïve and polarised macrophages  56 
 3.1.3 IL-12 secretion in naïve and polarised macrophages  59 
 3.1.4 TGF-βsecretion in naïve and polarised macrophages  62 




3.2 Western Blot Results       71 
 3.2.1 MAPK signalling in naïve and polarised macrophages  71 
 3.2.2 NF-κB signaling in naïve and polarised macrophages  77 
 
Chapter 4: Discussion       91 






Background and Aim 
Infection is a global burden causing millions of deaths per annum worldwide.  In the US 
sepsis is the tenth leading cause of death with the mortality associated with severe sepsis 
estimated at 30-50%. Innate immunity is a generic response mediated by the host to protect it 
from bacterial infection. The recognition of foreign microbes leads to activation of pattern 
recognition receptors and recruitment of macrophages. In acute bacterial infections, activated 
macrophages polarised to M1 or M2 states play a major role in the host cytokine response 
which drives the immune response until the host has overcome the invading microbial 
pathogen. The aim of this study was to 1) to characterise the cytokine profile of M1 and M2 
polarised macrophages 2) to investigate the changes in the cytokine profile of polarised 
macrophages in response to bacterial stimulation 3) to examine the role of the MAPK and 
NFκB signalling pathways in the response of naïve and polarised macrophages to bacterial 
infection.  
 
Results: (i) polarisation of macrophages to an M1 state resulted in a higher secretion of pro-
inflammatory cytokines (IL-6, IL12p70 and TNF-a.). (ii) following bacterial stimulation M1 
polarised macrophages had reduced pro-inflammatory cytokine release. (iii) M1 polarised 






Following bacterial stimulation M1 polarised macrophages had reduced pro-inflammatory 
cytokine release which may in part be due to reduced MAPK and NFκB signalling. This data 
suggests that M1 polarisation states may play important roles in an endotoxin tolerant 
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 “The presence in tissues of harmful bacteria and their toxins typically through 
infection of a wound” 
 -Oxford English Dictionary  
 
 
1.1 Sepsis  
1.1.1 Definition 
Sepsis, an age old enigma, was first recounted by Homer in the Iliad.1 The word is of Greek 
origin, literally meaning “I rot”. Sepsis was described by Hippocrates as the process by which 
“flesh rots, swamps generate foul airs and wounds fester”.2  Interestingly, Galen was one of 
the first to consider sepsis a necessary event in order to allow wound healing,3 but it was not 
until the research of Louis Pasteur that the definitive link between ‘germs’ and infection was 
demonstrated.4  Sepsis is defined as the probable or documented presence of microbial 
infection together with systemic manifestations of infection.5  It is a potentially life-
threatening condition, ranking in the top 10 causes of death.6 Sepsis occurs following a 
breach of integrity of any one of the host barriers, e.g. physical, immunological or direct 
penetration of the pathogen into the bloodstream.7  Physical barriers include the 




Several different terms have been used to describe the overwhelming inflammatory 
response associated with acute infections including sepsis, septicaemia and septic shock. This 
can lead to confusion in national and international reporting of sepsis. As a direct result of 
these confusing terms, a consensus meeting was convened in 1992.  At this conference, the 
American College of Chest Physicians/Society for Critical Care Medicine (ACCP/SCCM)8 
decided, following collaboration and consensus, upon a definition of sepsis as the presence of 
at least two out of four criteria listed in the table below as well as probable or documented 
infection.  
 
Definition of Sepsis The presence of two out of four of these criteria 
Temperature > 38° or < 36° Celsius 
Heart rate > 90 beats per minute 
Hyperventilation > 20 respirations per minute or PaCO2 < 32 mmHg 
White cell count > 12,000 cells/μL or < 4,000 cells/μL 
 
Table 1. Definition of systemic inflammatory response. Must incorporate at least two of the four 
criteria.  
 
These criteria were subsequently updated in the Society of Critical Care Medicine/European Society 
of Intensive Care Medicine/American College of Chest Physicians/American Thoracic 
Society/Surgical Infection Society (SCCM/ESICM/ACCP/ATS/SIS) International Sepsis Definitions 
Conference in 2001.9 (Table 2) The range of criteria included highlights the distinct difficulty that has 




Infection1: Documented or suspected and some of the following2  
General Parameters Fever (core temperature >38.3°C)  
Hypothermia (core temperature <36°C) 
Heart rate >90 beats per minute or >2SD above the normal value for age 
Tachypnoea >30 breaths per minute 
Altered mental state 
Significant oedema or positive fluid balance (>20ml/kg over 24 hours) 




Leukocytosis (white blood cell count >12,000/μL) 
Leukopaenia (white blood cell count <4,000/μL) 
Normal white blood cell count with >10% immature forms 
Plasma C reactive protein >2SD above the normal value 
Plasma procalcitonin >2SD above the normal value 
Haemodynamic 
Parameters 
Arterial hypotension2 (systolic blood pressure <90 mmHg, mean arterial pressure 
<70 or a systolic blood pressure decrease >40mmHg in adults or <2SD below 
normal for age) 
Mixed venous oxygen saturation >70% 
Cardiac index >3.5min-1m-2 (3,4) 
Organ Dysfunction 
Parameters 
Arterial hypoxaemia2 (PaO2/FiO2 <300) 
Acute oliguria (urine output <0.5ml/kg/hr or 45mM/L for at least 2 hours) 
Creatinine increase ≥0.5mg/dL 
Coagulation abnormalities (international normalised ratio >1.5 or activated partial 
thromboplastin time >60 seconds) 
Ileus (absent bowel sounds) 
Thrombocytopenia (platelet count <100,000/μL) 




Decreased capillary refill or mottling 
Table 2. Adapted from the Society of Critical Care Medicine/European Society of Intensive Care Medicine/American 
College of Chest Physicians/American Thoracic Society/Surgical Infection Society (SCCM/ESICM/ACCP/ATS/SIS) 
International Sepsis Definitions Conference in 2001. 
 
1. Defined as a pathological process induced by microorganisms.  
2. Values above 70% are normal in children and should therefore not be used as a sign of sepsis in newborns.  
3. Values of 3.5-5.5 are normal in children and should therefore not be used as a sign of sepsis in newborns or children.  
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4. Diagnostic criteria for sepsis in the paediatric population include signs and symptoms of inflammation plus infection with 
hyper or hypothermia, rectal temperature >38.5°C or >35°C, tachycardia (may be absent in hypothermic patients) and at 
least one of the following indications of altered organ function: altered mental status, hypoxaemia, elevated serum lactate 
and bounding pulses 
 
 
1.1.2 Incidence and mortality of sepsis  
Sepsis is a systemic, deleterious host response to infection leading to severe sepsis and septic 
shock. It is an important, but perhaps overlooked public health problem. Studies suggest that 
acute infections can often exacerbate pre-existing chronic conditions or result in new chronic 
diseases. In the US severe sepsis is the tenth leading cause of death, similar in number to 
those dying from acute myocardial infarction.  The risk of dying from sepsis is rising year on 




1.1.3 Risk factors in sepsis 
Risk factors for sepsis include those outlined in table 3. 
Table 3: Risk factors associated with sepsis  
Risk Factors for Sepsis Risk Factors associated with mortality in cases of 
severe sepsis 







Acute renal failure 
Shock 
Smoking 
Use of mechanical ventilation 
Dementia 
Advanced age 
Chronic liver disease 
Cardiac failure 
Treatment in the initial hours after the onset of sepsis significantly influences outcome. 
Variability exists in reported severe sepsis mortality, with a rate of 8.6% (range 0.9 – 18.2%) 
across 188 Hospitals in the US recently described,14 however a further study reported higher 
in-hospital mortality rates ranging from 14.7% to 29.9%.15   
 
Sepsis is also a global financial burden.16  The costs associated with sepsis care are mainly 
related to the price of targeted new therapies such as activated protein C, which costs $27,936 
per life year gained17, technologies and also the increasing charges for fixed costs.  Angus 
and co-workers estimated the cost of sepsis treatment in the United States in 2001 at $16.7 
billion annually.18  This figure had risen to $24.3 billion by 2007,19 highlighting the 




1.1.4 Aetiology of Sepsis 
Over 90% of cases of sepsis are caused by bacteria. Much less commonly, in approximately 
6% of cases, fungal causes are implicated; viral and parasitic causes are rare.6 The aetiology 
remains elusive in approximately 30% of cases of sepsis, due to the inability to isolate the 
offending pathogen.  
  
1.1.5 Bacterial sepsis 
Bacterial sepsis is a symptomatic bacteraemia with or without end organ dysfunction.  
Confirmation of microbial presence relies on culturing the pathogen from tissue samples e.g. 
pus or blood, in a dedicated microbiology laboratory. This process takes a minimum of 24 
hours, in order to allow growth of the organism, but is only positive in approximately 50% of 
cases6 making targeted narrow spectrum antibiotic therapy challenging. 
 
1.1.6 Classification of bacteria 
Hans Christian Joachim Gram, a Danish bacteriologist working in Berlin, devised a method 
in 1884, for dividing bacteria into two main groups: bacteria that have the ability to retain an 
initial crystal violet stain are termed gram-positive whereas those that are decolourised and 
stain red with carbol fuchsin are termed gram-negative.20  He did this by examining lungs 
from patients who had died from pneumonia. The two groups behave differently; 90-95% of 
Gram negative organisms are pathogenic, whereas many gram positive organisms are not 
pathogenic. However, it remains a fact, that the vast majority of severe sepsis cases are as a 
result of infection with gram-positive bacteria. 
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Table 4. Common pathogenic gram positive and gram negative bacteria 




















1.1.7 Aetiology of bacterial sepsis 
The incidence of gram-positive bacterial sepsis has increased over time and is now almost as 
common as gram-negative sepsis.6 In a 2006 European multicentre study of septic patients 
admitted to intensive care units, a respiratory source (68%) of sepsis was most common in 
68% of cases, followed by an intra-abdominal source in 22% of cases.21  The same study 
revealed the most common isolate as Staphylococcus aureus, followed by Pseudomonas 
species and Escherichia coli.  The Extended Prevalence of Infection in Intensive Care study 
(EPIC II), an international study of the prevalence and outcomes of infection in intensive care 
units also found a predominant respiratory source of sepsis (64%), with 62% of isolated 
bacteria identified as gram-negative microorganisms.22  The most commonly isolated gram-
negative bacteria in that study were Pseudomonas sp., Eschericia coli and Klebsiella sp..  
Staphylococcus aureus was one of the most commonly isolated gram-positive bacteria 
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followed by Staphylococcus epidermidis and Streptococcus pneumonia.  The same study, 
using multivariate analysis, found that gram-negative bacteria, namely Pseudomonas, 
Enterococcus and Acinetobacter sp., were associated with a greater risk of in-hospital 
mortality.  The increasing incidence of gram-positive infection is attributed to the increasing 
numbers of invasive procedures and the increasing risk of developing hospital acquired 
infections.23  
 
1.1.8 Pathophysiology of sepsis 
The precise pathophysiology involved in sepsis will be dealt with further in the chapter, but 
in brief, death from sepsis results from an overwhelming inflammatory cascade causing end-
organ damage and multi-organ failure.  When acting appropriately, the inflammatory 
response deals effectively with the invading organism without causing tissue or end organ 
damage. It is a complex interplay between anti-and pro-inflammatory signals and in most 
individuals the body is able to balance these competing tasks.  
 
1.1.9 Treatment of Sepsis 
The mainstay of sepsis care has been early broad-spectrum antibiotics and early goal-directed 
therapy. The concept of immune modulation in the treatment of sepsis is one of significant 
interest and ongoing research. Unfortunately, thus far, no immune modulator has proven 





1.1.10 Antibiotic therapy 
A delay in antibiotic treatment for bacteraemia has been shown to increase mortality.24 
Empiric antibiotic therapy should be commenced where a diagnosis of sepsis is suspected and 
after cultures have been taken. Selection of appropriate antibiotics depends on a number of 
different factors including: local antimicrobial guidelines, the suspected source of sepsis, 
whether the infection is likely to be community- or hospital-acquired, the presence of foreign 
bodies and the immune competency state of the patient among others. Once a pathogen is 
identified, often at least 24 hours after presentation, antibiotic therapy can be rationalised. 
 
1.1.11 Early Goal Directed Therapy 
This has been used for the treatment of severe sepsis and septic shock. Circulatory collapse in 
severe sepsis leads to an imbalance between tissue oxygenation and tissue oxygen 
requirements, resulting in shock.  Global tissue hypoxia is a precursor for the development of 
organ damage, multi-organ failure and death.25 The ‘golden hour’ is a window of opportunity 
that exists when aggressive management of physiological parameters can provide an outcome 
benefit.26 Optimised cardiac preload, afterload and contractility improves survival in septic 
patients.27 Aggressive fluid replacement therapy is the first line of treatment in maintaining 
cardiac output, however if blood pressure remains low despite fluid challenge then 
vasopressors are recommended.  
 
1.1.12 Immune Modulation 
Treatments directly targeting the immune response to sepsis have so far proven 
disappointingly expensive and ineffective, despite promising animal and preclinical results. 
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Recombinant human activated protein C (APC) is one such example of an immune modulator 
targeting severe inflammation in the treatment of adult and paediatric sepsis. APC has both 
anticoagulant and cytoprotective effects. The recombinant human activated protein C 
worldwide evaluation in severe sepsis (PROWESS) study group sought to prove a benefit in 
mortality rates in patients with severe sepsis who were treated with APC, however the 
outcome was that treatment with APC provided no mortality benefit at 28 or 90 days. A 
separate trial, the PROWESS-SHOCK trial sought to prove a benefit in mortality for patients 
with septic shock who were treated with APC, however, again there were no significant 
differences in mortality rates at 28 and 90 days.28 
Other studies have addressed TLR signaling in sepsis, including a TLR4 agonist TAK-242 
which showed great promise in pre-clinical trials but did not show any efficacy in phase 3 
clinical trials.29,30,31 
Recent studies have indicated a role for the high mobility group box 1 (HMGB1) as a late 
mediator in experimental sepsis. The potential role of HMGB1 inhibitors such as TSN-SS in 
the clinical management of human sepsis have produced promising results with TSN-SS 
attenuating late inflammatory response and improving cardiovascular function in Chinese 
cardiovascular patients (Wang et al., 2014). However, robust safety studies along with 
extensive preclinical toxicology studies are required before therapeutic intervention in human 
sepsis32.  
 
1.2 Immune response to sepsis 
Sir William Osler noted that death from sepsis resulted from the response of the body to 
systemic infection as opposed to the infection itself.  This view was expanded on in the 
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1970’s and is now a widely accepted concept.33   Death in the first few days from sepsis is 
generally understood to be a result of hyper-inflammation driven by inflammatory cytokines, 
leading to multi-organ failure.  People at the extremes of life are at increased vulnerability to 
infection.  In countries with good healthcare infrastructure, 75% of deaths from sepsis occur 
in those aged 65 and older.34  The immune system affords the host an opportunity to respond 
to pathogenic organisms and incorporates innate and adaptive immunity.  
 
1.2.1 Adaptive Immune Response 
Adaptive or acquired immunity is a separate, more sophisticated line of defence against 
pathogens as compared to the innate immune response. It is a learned and specific response to 
invading micro-organisms, not the generic response that is characteristic of innate immunity. 
Adaptive immunity is dependent on the “rearrangement of genes, antigen specific and 
requiring time for induction during primary challenges”.35  It is based in the recognition of 
antigens.  Adaptive immunity takes longer to respond and relies heavily on antigen presenting 
cells and the ability to recognise the offending antigen. B and T cells form the backbone of 
the adaptive immune response through the generation of immunoglobulins and the reaction of 
activated T cells directly against an antigen. The ability to differentiate what is self from what 
is foreign is fundamental to adaptive immunity. Allergic responses like hayfever and asthma 
are examples of the adaptive immune system attacking its own cells.36  
 
1.2.2 Innate immune response to sepsis 
A person’s survival is dependent on an innate immune system that can quickly recognise and 
respond to foreign pathogens such as bacterial and viral products.  Innate immunity is a 
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generic response and is the first line of defence in protecting the host from pathogens37.  It is 
defined as being “dependent on germline genes, present at all times and functional during 
early primary infections but not increasing with repeated exposure”.38 Animals detect 
invading microorganisms through a family of receptors called pathogen-associated molecular 
patterns (PAMPs)39.  PAMPs are detected by cells of the innate immune system, through 
pattern recognition receptors (PRRs), composed of four main families: toll-like receptors 
(TLRs), C-type lectin receptors, retinoic gene 1-like receptors and nucleotide binding 
oligomerisation domain-like receptors (NLRs).40  This generic immune response allows for 
the detection of a finite number of molecules that are common and conserved in different 
microbes, e.g. lipopolysaccharide (LPS) or lipid A, which is common to all gram-negative 
bacteria, or lipoteichoic acid (LTA) common to gram-positive bacteria. 
 
Macrophages, neutrophils and dendritic cells are all salient elements of the host innate 
immune response.  These cells can directly or indirectly target pathogenic microorganisms 
through phagocytosis or by releasing substances such as cytokines, chemokines and other 
mediators.  Phagocytosis by macrophages initiates the innate immune response.  This 
inflammatory response to invading pathogens is characterised by the release of a variety of 
different signalling molecules including inflammatory cytokines.  This vital step in the 
elimination of pathogens from the host can result in an overwhelming inflammatory response.  
Overproduction of pro-inflammatory mediators such as cytokines can lead to an amplified 
secondary response.  This hyper-inflammatory state, with loss of normal immune 




During an infectious or inflammatory state, circulating peripheral monocytes are recruited 
into tissues where they differentiate into macrophages.  Following this and dependant on the 
microenvironment present, macrophages can further differentiate into two main functional 
phenotypes or polarisation states; M1 or classically activated macrophages and M2 or 
alternatively activated macrophages. 
 
1.3 Macrophages 
Macrophages are important, essential, key components of the host innate and adaptive 
immune system and serve the purpose of initiating, maintaining and resolving the immune 
response to infection.  They are members of the mononuclear phagocyte system and derive 
from the myeloid lineage.  The spleen serves as a reservoir for immature monocytes41, and 
once mature, monocytes circulate haematogenously as peripheral blood mononuclear cells 
from between one to three days.  
 
Historically, it has been accepted that monocytes are macrophage precursors, serving to 
replenish macrophages and DCs both in ordinary circumstances and in response to 
inflammation or infection.42  However more recent data has suggested that adult tissue 
macrophages are actually derived from embryonic progenitor cells that seed developing 
tissues in utero.43 Notwithstanding this recent development, monocytes are still regarded as 
key players in replenishing tissue macrophages in the setting of inflammation, infection and 




Macrophages were first described by Elie Metchnikof in the late 1800’s,44 have a widespread 
tissue distribution, e.g. liver, gut, lung, brain, etc. and display remarkable phenotypic 
heterogeneity. Tissue macrophages have a repertoire of receptors with the purpose of 
identifying invading organisms. They do this through pattern recognition receptors (PRRs) 
which identify molecular patterns such as pathogen associated molecular patterns (PAMPs) 
or danger associated molecular patterns (DAMPs). The response of the macrophage varies 
depending on the nature45 and magnitude46 of the insult. Macrophages, following activation 
by a stimulus, can be split into two main polarisation profiles or phenotypes. M1 or 








Macrophages are found in many different tissues in the body. In the brain they are known as 
microglial cells, in the liver as kuppfer cells and at other sites as outlined above.  
1.3.1 M1 macrophages (classically activated) 
M1 macrophages are associated with infections such as Listeria monocytogenes,47 Salmonella 
typhimurium48, Escherichia coli,49 Streptococcus sp,50 early Mycobacterium 
tuberculosis,51Mycobacterium ulcerans52 and Mycobacterium avium.53  Animal experiments 
have shown that in Mycobacterium tuberculosis infection M1 macrophage induction is 
critical to the control of infection, whereas M2 macrophage polarisation supports intracellular 
persistence of the bacteria.54 
 
Pro-inflammatory cytokines such as TNF- α, IL-6, IL-12, induced by M1 macrophages are 
functional small protein molecules with low molecular weights.55  They are produced in a 
sequential fashion in response to triggering of the innate immune system by invading 
pathogens56. The M1 phenotype is characterised by high levels of these pro-inflammatory 
cytokines, the release of superoxide species and the promotion of a Th1 response57.  M1 
macrophages also display high phagocytic and bactericidal potential. Inducible nitric oxide 
(iNOS) which causes the breakdown of arginine to citrulline and nitric oxide, plays a key role 
in the killing of intracellular pathogens and is upregulated in M1 macrophages58.  
 
1.3.2 Signaling in M1 macrophages 
M1 macrophage polarisation is induced by activation of IRF/STAT signalling pathways by 
cytokines, such as IFNs and/or microbial products or LPS through recognition by the TLRs.  
STAT-mediated activation of macrophages is mediated by members of the SOCS family.  M1 
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macrophage polarisation was originally reported to require both IFN-g and TNF-a; however, 
TLR ligands activate the MyD88-dependent pathway,59 resulting in the generation of IFN-
b.60 This IFN-b can cause activation of classically activated macrophages.  M1 cells are 
reported to have an IL-12high IL23high IL-10low phenotype. 
The functions of IFN-g include enhanced microbial killing, increased antigen presentation 
and enhanced inflammatory cytokine production.61 IFN-g signals through the JAK-STAT 
pathway when activating of macrophages, stimulating STAT1 predominantly. Mice lacking 
IFN-g are more susceptible to infection with a variety of microorganisms including various 
bacterial, protozoal and viral infections.62,63 M1 macrophages have been induced in vitro 
using a combination of IFN-g (1x103 U/ml recombinant human IFN-g for 48 hours) and LPS 
(10 ng/ml for the last 24 hours of culture).64  IFN’s prime macrophages for prolonged and 
sustained expression of pro-inflammatory cytokine genes, in response to PAMPs.  IFN-g is a 
very potent inducer of the M1 polarization state65 and interestingly, prevents tolerance by 
preserving the expression of receptor-interacting protein 140 (RIP140) co-activator and 
promoting TLR-induced chromatin accessibility upon secondary TLR challenge.66,67 In 
addition to M1 or M2 activation states, macrophages can also enter a tolerant state. This 
tolerant state occurs whereby during either endotoxin shock or acute sepsis, a pro 
inflammatory cytokine response is induced, but importantly, on second endotoxin challenge 
macrophages can become hypo-responsive.68 As a result, pro- inflammatory responses are 
downregulated reducing collateral inflammatory damage. 
 
TNF-a and IL-1 are two of the most well studied pro-inflammatory cytokines.  TNF-a is a 17 
kDa protein that is released from macrophages within 30 minutes of the onset of a stimulus 
such as inflammation or invasive infection.  TNF-a enhances the production of macrophages 
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from progenitor cells69 and also encourages activation and differentiation of macrophages70 
as well as prolonged survival.71  IL-1 is also released predominantly by macrophages.  Both 
cytokines act together to induce a shock-like state which is characterised by vascular 
permeability and haemorrhage.72  
 
Numerous studies suggest that M1 polarisation affords protection during acute infections.73 
However when the M1 polarisation profile loses the normal homeostatic mechanisms then an 
exaggerated response is detrimental to the host, for example: in a baboon model of peritonitis, 
animals with a prominent M1 phenotype were more likely to die compared with those who 
had a mixed M1/M2 macrophage polarisation profile.74 
Table 5. Markers associated with M1 and M2 polarisation states 
M1 macrophages M2 macrophages 
High oxygen consumption Preferentially express receptors for foreign 
antigens 
Phagocytose intracellular pathogens 





pro-inflammatory cytokines (IL-1, IL-6, TNF-α) 
Th1 response associated cytokines (IFN-γ, IL-
12, IL-18) 
 Produce CCL17, CCL22 
 
Some differences exist between markers of M1 and M2 polarisation states in mice and 
humans and these are outlined in Table 6. Overall, the Th1 and Th2 responses are similar 
between the species, as well as the cytokine response.
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Table 6. Differences between M1 and M2 markers in humans and mice 
Properties Human Mouse 
M1 M2 M1 M2 





















CCR7 CCR2, CXCR1, 
CXCR2 
    
Bactericidal 
activity 
Yes No Yes No 
Inhibition of 
IFNγ production 
No Yes     
Th1/Th2 
polarisation 
Th1 response Th2 response Th1 response Th2 response 
Nitric oxide Yes – production 
of iNOS 
No – production 
of arginase 
Yes – production 
of iNOS 
No – production 
of arginase 
Cytokines TNFα, IL-12, 
IFNα/β, IFNγ 
IL-1Ra, IL-10 TNFα, IL-12, 
IFNα/β, IFNγ 
IL-1Ra, IL-10 






CCL3, CCL5 CCL17 
Specific 
molecules 





1.3.3 M2 macrophages 
M2 macrophages are involved in the resolution of inflammation and tissue repair, as well as 
angiogenesis and tumour progression.  In the 1990’s, a role for IL-4 in M2 macrophage 
polarisation was described.75  Polarisation of macrophages to the M2 profile is also induced 
by IL-13. IL-4 and IL-13 are both well-known activators of alternative macrophage 
phenotypes,76 as well as being associated with parasitic infections.  Other cytokines such as 
IL-33 and IL-25 can amplify M2 polarisation indirectly.77  Alternatively activated 
macrophages have well-described anti-inflammatory effects and have been characterised by 
high levels of TGF-β, IL-10, M-CSF.  M2 markers also include arginase-1 (Arg-1), mannose 
receptor (MR), chitinase 3-like 3 (Ym-1) and resisting-like molecule-a (RELM-a, also 
known as Fizz-1).  Other markers associated with this phenotype are IFN regulatory factor 5 
(IRF-5), Kruppel-like factor 4 (KLF-4), suppressor of cytokine signaling 1 (SOCS-1) and 
transglutaminase 2 (TGM2).78  M2 macrophages convert arginine to ornithine and urea 
through the action of Arg-1.79  Studies with IL-4R knockdown mice showed that they were 
highly susceptible to infection with Schistosoma mansoni, with mortality attributed to an M1-
driven cytokine response and elevated iNOS activity.80  IL-4 and IL-13 are associated with a 
Th2 type immune response, which is involved in the immune response to allergens and 
parasites.  IL-4 has a distinct function in skewing macrophage polarisation and is needed for 
efficient phagocytosis.  An M1 to M2 switch can occur during the change from acute to 
chronic infection and allows for protection from overwhelming inflammation, thus the M2 
polarization profile is linked with the persistence of pathogenic bacteria in tissues and the 
chronicity of infectious diseases. Once such bacterium which exploits this chronic M2 




Figure 2. M1 and M2 macrophages and their phenotypic differences 
M1 and M2 macrophages have varying phenotypic functions depending on their polarisation state. 
Highlighted above are the different polarising stimuli, characteristic markers, cytokine profiles and 




1.3.4 Role of macrophages in the immune system 
Macrophages are potent phagocytic cells that are involved in the clearance of cellular debris 
and cells that have undergone apoptosis.  They are rapidly recruited to wounds following 
platelet degranulation.82  They detect endogenous danger signals through the TLR family, 
other PRRs and IL-1R. The majority of these pathways signal through the adaptor protein 
MyD88.  Mosser and Edwards suggest three classifying categories for macrophages 
according to their functions: host defence, wound healing and immune response.76 
 
It is well established that macrophages display extraordinary plasticity with the ability to 
switch between phenotypes in vitro and in vivo.83 84 Macrophages display plasticity resulting 
in a spectrum of macrophage activation dependent on environmental signals.85  Phenotypic 
switches can occur in macrophage populations over time, but it is unclear whether this switch 
is due to switching of the macrophage phenotype back to the resting state, or whether it is due 
to infiltration of tissues with new populations of macrophages.76 Macrophages also exhibit 
numerous cell surface markers, which enable researchers to divide them into subpopulations 
based on their phenotypic functions.  Early warning signs can trigger macrophage activation 
and allow for macrophage recruitment and in situ activation and proliferation.86  The sensing 
of tissue damage enables further macrophage activation, allowing for the orchestration of the 
host immune defense.  Following this the production of anti-inflammatory signals, culminates 





1.3.5 Macrophage polarisation and its role in sepsis 
The term macrophage polarisation was first used by Mackaness in the 1960’s.87  Activation 
of macrophages has emerged as a key area of research.  Macrophages are involved in a wide 
variety of immune processes including immunology, tissue homeostasis, disease modulation 
and resolution of inflammation.  Macrophage activation can be influenced by a variety of 
factors including cytokines, pathogens and endotoxins.  Mills and colleagues suggested that 
macrophage polarisation be split into two categories as defined by the ability of M1 
macrophages to secrete NO and M2 macrophages to make trophic polyamines.88  M1 
macrophages are associated with a profound pro-inflammatory state, whereas M2 
macrophages are associated with an anti-inflammatory state.  These opposing effects are vital 
for regulation of the inflammatory response.  The massive pro-inflammatory response that is 
associated with bacterial infection must be tempered with a variety of regulatory anti-
inflammatory mechanisms in order to avoid a deleterious overwhelming inflammatory 
response.  The main mode of death in septic patients is multi-organ failure as a result of 
damage from the overwhelming release of pro-inflammatory cytokines.  Macrophage 
polarisation is driven by signals in the microenvironment, which shapes the phenotype of the 







Figure 3. Paradigm of macrophage activation (adapted from 89) 
There are different stages in the macrophage activation paradigm. Monocytes mature into 
macrophages in the presence of M-CSF and GM-CSF. Following this they can be primed by different 
stimuli including M-CSF and GM-CSF. Macrophages are polarised towards phenotypes by substances 
such as IL-4 and IFN-γ. M2 macrophages are involved in the resolution of inflammation and in tissue 





1.4 Signalling pathways involved in Sepsis 
1.4.1 Toll-like receptors 
The transmembrane TLRs with an extracellular domain involved in bacterial ligand 
recognition are the most widely described PRRs.  TLR1, TLR2, TLR4, TLR5, TLR6 and 
TLR10 are located at the extracellular surface, whereas TLR3, TLR7, TLR8 and TLR9 are 
located in the endoplasmic reticulum and endosomes.90,91,92,93 TLRs were initially 
investigated in Drosophila94, which has no adaptive immune system.95  Eleven TLRs have 
been discovered in humans and thirteen in mice96 and they or their homologues are found in 
all multi-cellular organisms.97  Species differences do occur in the TLRs, which complicates 
attempts at cross-species direct comparisons.  TLR2 and TLR4, which are expressed on the 
cell surface, are perhaps the most widely investigated of the TLR family and the only TLRs 
shown to be responsive to microbial ligands.98  LPS or endotoxin, derived from gram-
negative bacteria almost exclusively activates its primary receptor TLR4, one of the most 
studied pathways in host innate immunity against gram-negative bacterial infection.   
 
1.4.2 TLR4  
TLR4, initially named hToll was discovered in the 1990’s, when Hoshino and colleagues, 
using TLR4-deficient mice, demonstrated the hypo-responsiveness of these animals to LPS 
stimulation,99 thus confirming the pivotal role of TLR4 in the response to LPS.  TLR4-
deficient mice have been shown to be susceptible to gram-negative bacterial infection.  In 
addition, specially bred mice that exclusively expressed TLR4 on endothelial cells were 
found to be more efficient at clearing Escherichia coli infection.100  Smirnova et al, on 
examining DNA from patients with meningococcal disease found that a variant in the TLR4 
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gene is associated with an increased susceptibility to meningococcal septicaemia.101  Genetic 
variants in the TLR4 have also been linked to gram-negative bacterial infection in 
neonates.102   
 
1.4.3 TLR2 
TLR2, on the other hand, forms heterodimers TLR2/TLR1 and TLR2/TLR6 with either 
TLR1 or TLR6, and is a functional receptor for components of gram-positive bacteria 
including LTA, peptidoglycan (PGN) and bacterial lipopeptides, thus being responsible for 
the detection of gram-positive bacteria.103,104,105 TLR2-deficient mice are highly susceptible 
to gram-negative Staphylococcus aureus infection, with significantly attenuated TNF-α and 
IL-6 production.106 TLR5 and TLR9 recognize flagellin of bacteria flagella and bacterial 
CpG-DNA,107,108 respectively. 
 
1.4.4 TLR signaling in sepsis 
Upon engagement with their specific ligands, TLRs activate several intracellular signalling 
pathways.  Signalling by TLRs in humans involves a family of five adaptor proteins, which 
interact with downstream protein kinases that ultimately lead to the activation of transcription 
factors including nuclear factor-kB (NF-kB) and members of the interferon (IFN)-regulatory 
factor (IRF) family.  The Toll/interleukin-1 (IL-1) receptor (TIR) domain, which is unique to 
the TLR system, is the key signalling domain for not only TLRs but also the adaptor protein.  
These five adaptor proteins include myeloid differentiation factor 88 (MyD88), MyD88 
adaptor-like protein (MAL), TIR-domain-containing adaptor protein inducing IFN-b (TRIF), 
TRIF-related adaptor molecule (TRAM) and sterile-a and armadillo-motif-containing protein 
(SARM).109  MAL, TRIF and TRAM are also known as TIR domain-containing adaptor 
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protein (TIRAP), TIR-containing adaptor molecule-1 (TICAM1) and TICAM2.  All TLRs 
(except TLR3) activate the MyD88 pathway, which results in the activation predominantly of 
the downstream NF-kB and mitogen-activated protein kinase (MAPK) signalling pathways, 
and ultimately leads to the production of inflammatory cytokines.   
 
 
1.4.5 MyD88 dependent pathway 
Upon stimulation, MyD88 recruits IL-1 receptor-associated kinase (IRAK) family to TLRs, 
and IRAK1 then associates with TNF receptor-associated factor 6 (TRAF6).  This 
subsequently leads to the activation of NF-kB as well as MAPKs including p38, c-Jun NH2-
terminal kinase (JNK) and extracellular signal-related kinase 1/2 (ERK1/2).110 Macrophages 
and DCs isolated from MyD88-deficient mice have been shown to be unable to respond to 
certain TLR ligands including TLR2, TLR5, TLR7 and TLR9,111 indicating that these TLRs 
are fully dependent on the MyD88 signalling in order to activate the NF-kB signalling 
pathway.  These cells however can remain somewhat responsive to LPS stimulation through a 
MyD88-independent pathway.  TLR3 and TLR4 can activate a MyD88-independent/TRIF-
dependent pathway, which allows for the activation of NF-kB and IRF3, and induction of 
IFN-β. TRIF (also known as TICAM1) activates TRAF3 and TRAF6, and signalling from 
TRAF3 induces IRF3 activation and allows for the production of IFN-b.  Mice lacking TRIF 
fail to generate a type I IFN response to LPS stimulation, though their ability to activate the 
NF-kB and MAPK signalling pathways is preserved.112 TRAM links TRIF to TLR4, and 
studies have shown TLR4 to possess the most complex signalling mechanism of all the 
TLRs, as TLR4 is the only member of the TLR family that recruits four adaptor proteins 
MyD88, MAL, TRIF and TRAM and activates two signalling pathways, namely the MyD88- 




1.4.6 p38 MAPK signaling in sepsis 
The p38 family is a major player in the host inflammatory response, particularly in 
macrophages.  It is activated in response to a variety of stimuli, including pathogens, 
cytokines, growth factors and UV radiation114.  P38 signalling varies depending on the 
stimulus.  p38 has four distinct isotypes; a, b, g and d.  The expression of inflammatory 
mediators, e.g. IL-1b, TNF-a, PGE2, IL-12, COX-2, IL-8, IL-6, IL-3, IL-2 and IL-1 on 
macrophages is mediated by p38a.  p38 allows for the binding of NF-kB to targets on IL-8 
and MCP-1.  Endotoxin, TNF-a, platelet aggregating factor (PAF) and IL-1 induce p38 in 
innate immune cells, which is an essential step for the release of inflammatory cytokines and 
chemokines, though when there is prolonged activation of p38 a hypoimmune state can 
occur, which is associated with the latter stages of sepsis.  Recent studies have described an 
impaired pro-inflammatory response of macrophages from septic patients to in vitro 
stimulation with CD40L, while survival is associated with the recovery of a pro-
inflammatory response115. This impaired response is related to the antigen presenting capacity 
of macrophages is septic patients which becomes impaired by 24hours and recovers only 
after up to 14 days.116  In survivors of sepsis other studies demonstrated 19 of 14,500 genes 
were overexpressed and these were mainly involved in the innate immune response.117 
 
MAPKs are Ser-Thr kinases, which activate a number of transcription factors.  There are 
three main MAPK pathways; the ERK1/2 pathway, p38 pathway and JNK pathway.  The 
MAPK pathways are activated by a number of phosphorylation events beginning with 
phosphorylation of the MAPK kinases at 2 serine residues by MAPK kinase kinases (MKKs).  
These activated MAPK kinases phosphorylate MAPKs at the threonine and tyrosine residues.  
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Activated MAPKs phosphorylate a wide variety of downstream molecules including protein 
kinases and transcription factors.  MAPKs can affect the transcriptional regulation of 
mRNAs, thereby modifying their stability, transport and translation.118  These signalling 
cascades are involved in many normal cellular functions but are also activated in a variety of 
pathologies including septic shock.119  The MAPK signalling pathways mediates the release 
of a number of different inflammatory cytokines in cells exposed to bacterial stimulation.120  
Bone marrow-derived macrophages (BMDMs) grow in response to a number of different 
stimuli including colony-stimulating factor-1 (CSF-1) or macrophage colony-stimulating 
factor (M-CSF), which allows for progenitor cells to mature into monocytes and 
macrophages and for their survival and activation into mature macrophages.  In BMDMs, 
stimulation with M-CSF activates the MAPK signaling pathway.121  
 
In addition to the above, MAPK is involved in the regulation of inducible nitric oxide 
synthase (iNOS), which is an important marker of M1 polarisation.  Nitric oxide has a 
number of important functions in the immune response; it is involved in tumour cell death, 
killing of intracellular pathogens, vasodilatation, inhibition of platelet aggregation and 
neurotransmission.122  There are three forms of NOS; endothelial, neuronal and inducible. 
Increased expression of iNOS is associated with sepsis as well as other conditions such as 






Figure 4. Schematic representation of TLR, MAPK and NF-kB signalling in sepsis 
30 
 
1.5 Endotoxin tolerance 
The host response to microbial infection involves a period of massive inflammatory cytokine 
production.  This is then followed by a period known as endotoxin tolerance, when the host 
becomes hyporesponsive to stimulation with LPS.  This was first described in animals that 
were injected with a sub-lethal dose of bacterial endotoxin and followed by a fatal dose.  Paul 
Beeson reported on endotoxin tolerance in 1946 when he described the abrogation of fever in 
rabbits undergoing repeated injections of typhoid vaccine.123  In animal models, two phases 
of endotoxin tolerance have been outlined: an early phase characterised by altered cellular 
activation and a later phase associated with the development of specific antibodies against the 
polysaccharide side chain of gram-negative organisms.124  Monocytes and macrophages 
exposed to endotoxin for between 3 and 24 hours became tolerant and display an altered 
response to re-challenge with bacterial endotoxin or lipopolysaccharide.  One study showed 
that treatment of human monocytes with LPS for even one hour could induce an endotoxin 
tolerant state.125 This is important because there is a multitude of evidence supporting the fact 
that immune cells, mainly monocytes and macrophages, from patients with sepsis display 
many of the characteristics of endotoxin tolerance.126 
 
1.5.1 The role of endotoxin tolerance in sepsis 
Endotoxin tolerance is associated with protection against tissue damage and mortality in 
animal models of sepsis.  It is not an anti-inflammatory state, but more a cellular 
reprogramming leading to immune hypo-responsiveness.127  The association between 
endotoxin tolerance and sepsis is very strong.  Circulating monocytes isolated from patients 
with sepsis have shown similar characteristics to that seen in endotoxin tolerance.125 In vitro 
and in vivo models of endotoxin tolerance exist, classically where cells are stimulated twice 
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with LPS.  Initially a low or sub-lethal dose of LPS is administered which is followed by 
administration of a higher dose.  For example, when peripheral blood mononuclear cells are 
isolated from septic patients and exposed to LPS or other TLR4 ligands they are shown to 
develop a hypo-responsiveness to a second stimulus.  The period of hypo-responsiveness to a 
second dose of LPS is time-dependent and previous work has demonstrated that cells regain 
the ability to mount a pro-inflammatory response after 5 days.128  
 
1.5.2 Similarities between endotoxin tolerance and the M2 macrophage polarisation 
profile 
Many of the characteristics of endotoxin tolerance resemble the immunosuppressive M2 
macrophage phenotype.  Endotoxin tolerant monocytes are however, different to the M2 
macrophage polarisation phenotype, which is dependent on the context, stimulus and method 
of tolerisation.  In murine models of endotoxin tolerance, IL-6 and IFN-g released following 
LPS challenge are dramatically reduced but IL-12p70 is not as significantly reduced.129  
TNF-a is the best marker of endotoxin tolerance, because of its significantly reduced 
production in tolerised cells.130  The suppressed production of pro-inflammatory cytokines is 
as a result of alterations in the NF-kB and MAPK signalling pathways.  Previous research has 
demonstrated that pretreatment of macrophages with IL-4 does not reduce the LPS-induced 
expression of pro-inflammatory genes, MAPK activation or NF-kB binding.131  
 
Interestingly, it is well established that IFN-g rescues monocytes and macrophages from 
endotoxin tolerance.132,133,126 In the absence of IFN-g or GM-MCSF, TLR or TNF-a induces 




NF-kB is essential for the optimum production of pro-inflammatory cytokines in 
inflammation.  Tolerance is associated with impaired NF-kB activation and a reduction in the 
p65 and p50 heterodimer binding and pro inflammatory gene transcription. The production of 
IFN-β which polarizes macrophages to an M1 state is suppressed by p50 NF-kB inhibition of 
NF-kB signalling.68 Studies have shown a reduced level of NF-kB in survivors of sepsis, 
while non-survivors had a prominent inactive homodimer compared to controls.135  Following 
stimulation with LPS, the peripheral blood mononuclear cells of septic patients produce 
lower levels of NF-kB, similar to those seen during tolerisation.  
 
Transcriptional profiling in macrophages has revealed two sets of LPS responsiveness genes: 
those that are tolerizable, e.g. TNF-a and IL-6, and those that are non-tolerizable, e.g. 
antimicrobial and anti-inflammatory genes.  Chromatin changes are associated with LPS 
tolerance and it is postulated that this transcriptional signature drives a phenotypic switch in 
macrophage polarisation, from a pro-inflammatory to an anti-inflammatory phenotype.127  
LPS tolerance switches macrophages to an anti-inflammatory phenotype which is distinct 
from an M2 phenotype.131 Alternatively, activated macrophages induced by IL-4, retain the 
ability to respond to TLR ligands and can induce pro-inflammatory cytokines.131 Recovery 
from LPS tolerance may allow macrophages to mount an efficient immune response, while 






Through a variety of signaling pathways, invading pathogens are sensed through pathogen 
recognition receptors and an immune response is mounted. When acting appropriately this 
response will result in the elimination of the bacteria and resolution of inflammation with the 
minimum of tissue damage. The immune response can, however, deviate from its normal 
homeostatic mechanisms and result in massive tissue damage, end organ damage and multi-
organ failure from an overwhelming immune response.  Macrophages are the backbone of the 
immune response, from their role in detecting invading pathogens through PRRs, to the 
activation of signaling pathways and the release of pro-inflammatory cytokines. The two 
main macrophage polarisation states, M1 and M2 have varying functions from mounting the 
acute cytokine response to their activity in tissue remodelling and repair. Being able to 
manipulate or direct the immune response is potentially very useful, from switching off the 
overwhelmingly M1 reaction to switching M2 macrophages back to an M1 state during the 
immune hyporesponsive period that can occur.  
 
The aim of this thesis is; To characterise the response of naïve and polarised macrophages in 
an ex –vivo model of bacterial infection.  
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Sepsis is a lethal condition. Jim Henson, the creator of The Muppets TV show 
died from Streptococcus pyogenes sepsis in 1990 at the age of 53. He developed a 
pneumonia, that rapidly progressed to sepsis associated multi-organ failure and 
consequently, death. Others who have died from sepsis include Alexander of Greece (a 
monkey bite), James Garfield (infected gunshot wounds), Napolean III (gallbladder 
sepsis), William Hewson (a surgeon who died from sepsis after dissecting a cadaver) and 
Mary Wollstonecraft, an English feminist (puerperal fever). More recently, Rory 
Staunton, the 12-year-old son of Irish immigrants to the USA, died from undiagnosed 
streptococcal sepsis, which developed from an infected cut the boy sustained to his elbow 
during an indoor basketball match. His parents have dedicated their time to raising 
awareness of sepsis and instituting ‘Rory’s regulations’ in New York City hospitals, 
which aim for early identification and treatment of sepsis. Despite the improved 
recognition of sepsis however, United States data show that cases have risen from 82.7 
cases per 100,000 in 1979 to 240.4 cases per 100,000 in 2000.1  
 
Research into immune modulation in sepsis began in the 1960’s when 
corticosteroids were used to dampen down the immune response in severe sepsis. 
However, clinical trials have failed to show a definitive benefit for the use of steroids in 
septic patients. Recently, a meta-analysis showed that short courses of glucocorticoids 
actually reduced survival in sepsis but that physiological levels of hydrocortisone 
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improved survival rates in patients with vasopressor-dependent shock.2 A more recent 
study has found that evidence is still lacking to either support or refute the use of steroids 
at any dose in patients with sepsis.3  
 
One of the better-known targets in the treatment of sepsis is LPS, however 
attempts to inject an endotoxin antiserum were unsuccessful in reducing mortality. 
Another molecule, TNF-α, has been targeted in clinical trials. A recent meta-analysis 
examining the use of anti-TNF agents in sepsis found that they produce only a modest 
decrease in the risk of dying from sepsis.4 Other molecules targeted include, IL-1, platelet 
activating factor and nitric oxide. Overall there have been over 100 Phase II and III 
clinical trials investigating compounds that target endogenous mediator molecules either 
in a discriminatory or non-discriminatory manner.5  
 
An understudied aspect of the immune response to sepsis, are macrophages. 
Macrophages are amazingly diverse cells, with a unique ability to kill invading pathogens 
within hours. They are the first line in the host defense mechanism.  
M1 polarisation of macrophages is induced by priming the cells with LPS and IFN-γ, M2 
activation is induced by priming cells with IL-4.6 Chartouni et al suggested that 
macrophages are simply primed by their respective stimuli and not activated until they 
come into contact with microbial stimuli.7 Recent research allowed for the proteomic 
profiling of M1 macrophages.8 Feng et al polarised macrophages towards an M1 and M2 
polarisation profile using LPS/IFN-γ	and IL-4 respectively. They found significantly 
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higher levels of TNF-α and IL-6 in M1 polarised macrophages compared with untreated 
and M2 macrophages,9 which is consistent with these data. 
A prior study demonstrated that pre-treatment of wild type macrophages with IL-
4 (the protoypic direct inducer of M2 macrophages) did not induce an endotoxin tolerant 
state. This is important to note, as IL-4 was used in this study as the prototypic inducer of 
M2 macrophages prior to treatment with bacteria. M2 macrophages are known to 
resemble a tolerant state, which is separate to their inducing stimuli.  Dabritz et al 
discovered that monocytes polarised with GM-CSF, were similar to monocytes treated 
with IL-4 and displayed increased production of IL-1β	and TNF-α, following stimulation 
with LPS, compared with control monocytes.10 The polarised cells were subsequently 
injected into clodronate treated mice and the animals subjected to a CLP model of sepsis. 
Animals injected with M2 polarised macrophages had a better survival rate than animals 
injected with M1 polarised macrophages.  This was backed up by clinical experiments in 
baboons in which the animals were implanted with an E. coli laden fibrin clot. Animals 
with a mixed M1/M2 macrophage polarisation profile, as defined by assessment of 
peripheral blood mononuclear cells, were found to have a survival advantage compared 
with those who had a prominent M1 polarisation profile.11  
 
This study sought to examine the response of polarized macrophages in response 
to bacterial stimulation. The concept of therapeutic macrophage manipulation in the 
treatment of sepsis is promising. Targeting macrophages and their polarisation profiles 
could allow for the immune response to be directed towards an M1 or M2 pathway. This 
has potential benefits in dampening down the overwhelming immune response that is 
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associated with sepsis and septic shock, and which is driven by M1 macrophages. It is 
proposed that macrophages could be isolated from a patients own serum, and 
subsequently polarised to an M2 phenotype. Following this the polarised macrophages 
could be re-introduced into the patient. M2 macrophages have potent anti-inflammatory 
effects and participate in a negative feedback loop to dampen down the M1 response. An 
attractive potential of this type of treatment is the ability to use the body!s own defenses, 
negating potential risks from donor sources.  
 
The immune response to sepsis is an extraordinarily complex mechanism with multiple 
interconnected pathways. The concept of therapeutic macrophage manipulation should 
allow for all aspects of the inflammatory signaling pathways to be modified based on the 
polarisation profile of the exogenously polarised macrophages.  
 
In this set of experiments, the cytokine profile of naïve and polarised 
macrophages was investigated at baseline and following stimulation with gram-positive 
and gram-negative bacteria. M1 polarised bacteria had significantly higher levels of pro-
inflammatory cytokines at baseline compared with naïve and M2 polarised macrophages. 
Following stimulation with both gram positive and gram-negative bacteria, M1 polarised 
macrophages were seen to have much suppressed production of pro-inflammatory 
cytokines compared with naïve and M2 macrophages. These results indicated that M1 
polarised macrophages exposed to bacterial stimulation were displaying an endotoxin 
tolerance like phenomenon.  
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Endotoxin tolerance is known to be a protective mechanism in which cells 
exposed to low concentrations of endotoxin, enter a period of hypo-responsiveness to 
further challenges with endotoxin. Endotoxin tolerance is associated with a reduction in 
the production of pro-inflammatory cytokines. However, septic patients, who develop a 
period of immune hypo-responsiveness after the initial cytokine storm, can display 
greater susceptibility to secondary infection leading to susceptibility to superimposed 
infections and a higher risk of death. M2 macrophages are classically associated with 
resolution of inflammation and tissue repair. Studies have demonstrated a possible 
relationship between M2 macrophage polarisation and endotoxin tolerance. Pena et al 
reported that endotoxin tolerant macrophages represented a distinct state of M2 
polarisation.12 By investigating the gene expression microarray profile among LPS 
treated, LPS tolerant and M2 polarised macrophages, it was found that tolerant cells have 
a gene expression profile more closely resembling M2 polarised macrophages. 
 
 Inflammation, or the body’s response to infection, is essential in overcoming 
infection, and involves activation of the immune system. This inflammatory response is 
under strict control, with the ultimate goal involving elimination of the offending 
microorganism. Initially the host must sense the invading organism through pattern 
recognition receptors. Specific mechanisms exist for both the recognition of Gram 
positive and gram-negative organisms. Lipid A is a component of Gram-negative 
bacterial cell walls and is detected by TLR4. LTA is a component of Gram-positive 
bacterial cell walls and is detected by TLR2. Cytokines released following the 
recognition of these bacterial components, are vital effectors in directing the host innate 
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immune response to infection.  Activated macrophages are one of the main stimuli for the 
release of pro-inflammatory cytokines such as TNF, IL-6 and IL-12. 
 
 An M1 polarization profile is associated with an effective immune response to 
bacterial infection.13 Flohe et al showed that IFN-γ	can cause dendritic cells from septic 
mice to recover the ability to secrete IL-12, within 6 hours of induction. Hessle et al 
suggested that gram-positive bacteria have a greater capacity to induce IL-12, whereas 
gram negative bacteria were more likely to induce IL-10.14  Other research has shown an 
inhibitory effect of TNF-α on the production of IL-12p70.15 This may explain the lack of 
any statistical difference between IL-12p70 levels in murine macrophages exposed to 
Staphylococcus aureus. Strindhall et al, looked at various clinical isolates of 
staphylococcus and discovered that different isolates varied in their ability to stimulate a 
pro-inflammatory response in human endothelial cells.16 (These were isolates taken from 
individual patients e.g., patients with skin or mucosal infections, and were a mix of S 
aureus and methicillin resistant S aureus). In this study pure isolates of Staph Aureus 
were used, circumventing this issue. 
 
In this study M1 macrophages had reduced production of pro-inflammatory cytokines compared 
with naïve and M2. This was not something that we had expected and is in contrast to previous 
studies. Research has shown that in septic patients, levels of IL-6, on stimulation with LPS, are 
severely blunted from Day 1 onwards. This suggests host immunosuppression might be 
responsible for the late deaths seen in patients suffering from sepsis.17,18 M1 macrophages are 
classically pro-inflammatory and microbicidal, whereas M2 macrophages are classically anti-
inflammatory and play an immunomodulatory role. The typical response to bacterial infection 
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involves the upregulation of genes involved in M1 polarisation,19 including IL-6, TNF-α and IL-
12. IL-6 is also a pro-coagulation mediator,20 with coagulopathy being a sign of severe sepsis.  
Previous studies have shown that M1 macrophages produce higher amounts of IL-6 on 
stimulation with bacteria. Staphylococcus aureus is able to stimulate production of IL-6 
in T-cells and monocytes from whole human blood.21 Bost et al., found high levels of IL-
6 and IL-12 in murine osteoblasts infected with Staphylococcus aureus.  Salmonella typhi 
treatment of human epithelial cells has previously been shown to be associated with 
elevated levels of IL-6.22 Mathur et al looked at the response of mice to Salmonella 
typhimurium infection and discovered elevated levels of serum IL-6 following infection 
which was ameliorated in TLR11 knockout mice.23 In this study M1 macrophages had 
reduced production of pro-inflammatory cytokines compared with naïve and M2 
macrophages. Recent studies have shown despite the M1-M2 paradigm depending on the 
site of inflammation a mixed population of macrophages can be present. Bystrom et al., 
used an in vivo model for acute inflammation and showed that the macrophages found 
during the resolution phase are the same as the cells that had migrated into the inflamed 
site during the pro-inflammatory phase.24 Further, polarisation of macrophages to M1 or 
M2 phenotype is more representative of a continuum state and a clear dichotomy is not 
always present.25 In these experiments, other factors such as length of stimulation of 
macrophages and concentrations of stimulus may have been a factor. 
The polarisation of macrophages is a highly dynamic process. Different concentrations of 
bacteria can elicit different cellular effects.  An elegant study by Sedivy-Haley et al., 
demonstrated that when exposed to different concentrations of bacteria, M1 polarised 
macrophages are relatively resistant to intracellular Salmonella typhi.26 Moreover, 
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although the mechanism remains to be fully elucidated a recent study suggests that 




Phagocytosis is an important function of the initial host innate immune response to 
microbial infection. Macrophages undergoing M2 polarisation tend to display enhance 
phagocytosis capabilities.27 Tolerance to LPS may protect against bacterial infection. A 
study examining the fungicidal phagocytosis capabilities of endotoxin tolerant 
macrophages found diminished phagocytosis capabilities in tolerant macrophages.28 The 
same study also found higher levels of NO production in the tolerant macrophages. A 
study from 2003 reported suppressed expression of two phagocytic receptors, CR3 and 
FcγIII/IIR, in LPS tolerant murine macrophages.29  This study showed equivalent 
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